RedHill Biopharma Ltd. filed its 6-K report on August 29, 2024, detailing financial results for the first half of 2024, including unaudited figures as of June 30, 2024, which reflect their recent business highlights and R&D progress. This filing is significant for investors as it updates on the company's financial performance and strategic developments since the previous reporting period.